Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imdusiran + Durvalumab in Chronic HBV
NCT06245291Phase 2Withdrawn
- Sponsor
- Arbutus Biopharma Corporation
- Start
- May 2024
- Primary completion
- Aug 2024
- Modality
- Gene Editing, Gene Silencing, Conjugated siRNA
- Countries
- 8
01
Overview
A Phase 2 trial of imdusiran in Chronic Hepatitis B (CHB), sponsored by Arbutus Biopharma Corporation. Planned start May 2024; status: withdrawn.
02
Drugs
imdusiran
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06245291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06245291.